Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Policy
Chinese court rules in Novozymes’ favor
by Jean-François Tremblay
February 27, 2017
| A version of this story appeared in
Volume 95, Issue 9
The Supreme People’s Court of China has ruled against two Chinese companies accused of infringing Novozymes’ patent on a glucoamylase enzyme used to make fuel and beverage ethanol. Shandong Longda Bio-Products and Jiangsu Boli Bioproducts had initially been found in violation of the Novozymes patent by a lower court in 2011, but the companies appealed, arguing against the patent’s validity. Novozymes says the legal win will encourage further development of the Chinese biotechnology industry.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter